Autopsy report · NCT03925324

Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device

“Lack of funding/Covid-19”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 3 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Medstar Health Research Institute

Sponsor type

University, hospital or other

Conditions

Ischemic Heart Disease; Non-ischemic Cardiomyopathy

Interventions

Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC); Placebo

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• RESIST-2: 2nd-line ART for HIV-2 Infection
  “COVID-19 and Funding” (87% match in meaning)
• High Risk Outpatient Intern-led Care (HeROIC) Clinic Initiative
  “Covid-19, funding” (85% match in meaning)
• Virtual Reality for the Treatment of Chronic Low Back Pain
  “Due to the impact of COVID-19” (75% match in meaning)
• Three Dimensional Facial Growth Analysis
  “Due to Covid-19 pandemic” (75% match in meaning)
• Systematic Work Environment Model Incorporating Web-based Neck-specific Exercise for Dental Staff With Neck Pain
  “Lack of fundings” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.